A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 881-886

  Ou, Yen Chuan ^a,b,c   Gardner, Thomas A ^d   Kao, Chinghaj ^d   Zhau, Haiyen E ^e   Chung, Leland W ^e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHI NAN UNIVERSITY   (Taiwan)

^d Indiana Cancer Pavilion   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbonic anhydrase IX (CA IX); Gene therapy; MN protein; Renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; LUCIFERASE; MN PROTEIN; PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; ENHANCER REGION; GENE ACTIVITY; GENE THERAPY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MOLECULAR CLONING; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TATA BOX; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; GENE THERAPY; GENES, REPORTER; HELA CELLS; HUMANS; KIDNEY NEOPLASMS; LUCIFERASES; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 17444376451     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ou YC, Yang CR, Ho HC, Cheng CL, Kao YL, Su CK, Chiu KY and Chen WM: The symptoms of renal cell carcinoma related to patients' survival. J Chin Med Assoc 66: 537-43, 2003.
2. Mulders P, Bleumer I, Debruyne F, Oosterwijk E: Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN). Urologe A 43(Suppl 3): 146-7, 2004.
3. Jongmans W, van den Oudenalder K, Tiemessen DM, Molkenboer J, Willemsen R, Mulders PF and Oosterwijk E: Targeting of adenovirus to human renal cell carcinoma cells. Urology 62: 559-65, 2003.
4. Der CJ and Stranbridge EJ: A tumor-specific membrane phosphoprotein maker in human cell hybrids. Cell 26: 429-38, 1981.
5. Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J and Zeiinik V: Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54: 268-74, 1993.
6. Mckiernan JM, Bunyan R, Bander NH, Stifeman MD, Katz AE, Chen MW, Olsson CA and Sawczuk IS: Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 57: 2362-5, 1997.
7. Liao SY, Aureho ON, Jan K, Zayada J and Stranbridge EJ: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57: 2827-31, 1997.
8. Bui MHT, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huand Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA and Belldegrum AS: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802-11, 2003.
9. Oosterwij E, Ruiter DJ, Hoedemaeker PJ, Pauwel EKJ, Jonas U, Zwartendijk J and Warnaar SO: Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. J Cancer 38: 489-94, 1986.
10. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zeiinik V, Opavsky R, Zativicova M, Liao S, Portell D, Stranbridge EJ, Zavada J, Burby A and Kettmann R: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9: 2877-89, 1994.
11. Opavsky R, Pastorekova S, Zeinik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R and Pastorek J: Human MN/CA 9, a novel membrane of the carbonic anhydrase family: structure and exon to protein domain relationship. Genomics 33: 480-7, 1996.
12. Ebert T, Bander NH, Finstad CL, Ramsawak RD and Old LJ: Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 50: 5531-6, 1990.
13. De Wet JR, Wood KV, De Luca M, Helinski DR and Subiumani S: Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7: 725-31, 1987.
14. Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ and Lerman MI: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95: 12596-601, 1998.
15. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The "bystander" effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-83, 1993.
16. Richards CA, Austin EA, Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-93, 1995.